Embree Financial Group Sells 45 Shares of Danaher Co. (NYSE:DHR)

Embree Financial Group decreased its position in Danaher Co. (NYSE:DHR) by 2.9% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 1,482 shares of the conglomerate’s stock after selling 45 shares during the period. Embree Financial Group’s holdings in Danaher were worth $370,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. ST Germain D J Co. Inc. grew its position in shares of Danaher by 1.4% in the first quarter. ST Germain D J Co. Inc. now owns 2,880 shares of the conglomerate’s stock valued at $719,000 after purchasing an additional 41 shares in the last quarter. Godsey & Gibb Inc. grew its position in shares of Danaher by 3.0% in the first quarter. Godsey & Gibb Inc. now owns 1,442 shares of the conglomerate’s stock valued at $360,000 after purchasing an additional 42 shares in the last quarter. Nicholas Hoffman & Company LLC. grew its position in shares of Danaher by 2.3% in the fourth quarter. Nicholas Hoffman & Company LLC. now owns 1,899 shares of the conglomerate’s stock valued at $439,000 after purchasing an additional 43 shares in the last quarter. Los Angeles Capital Management LLC grew its position in shares of Danaher by 1.3% in the fourth quarter. Los Angeles Capital Management LLC now owns 3,470 shares of the conglomerate’s stock valued at $803,000 after purchasing an additional 43 shares in the last quarter. Finally, Berger Financial Group Inc grew its position in shares of Danaher by 1.7% in the fourth quarter. Berger Financial Group Inc now owns 2,517 shares of the conglomerate’s stock valued at $582,000 after purchasing an additional 43 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling at Danaher

In other Danaher news, CEO Rainer Blair sold 9,005 shares of the company’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the completion of the transaction, the chief executive officer now owns 106,990 shares of the company’s stock, valued at approximately $28,352,350. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Danaher news, CEO Rainer Blair sold 9,005 shares of the company’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the transaction, the chief executive officer now owns 106,990 shares in the company, valued at approximately $28,352,350. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Matthew Mcgrew sold 46,377 shares of the company’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $253.05, for a total value of $11,735,699.85. Following the transaction, the chief financial officer now owns 29,407 shares in the company, valued at approximately $7,441,441.35. The disclosure for this sale can be found here. Insiders sold 148,783 shares of company stock valued at $37,536,717 in the last 90 days. Insiders own 10.90% of the company’s stock.

Danaher Trading Up 1.0 %

Shares of NYSE DHR traded up $2.41 during midday trading on Wednesday, reaching $242.20. The company had a trading volume of 2,090,825 shares, compared to its average volume of 2,861,986. The firm’s fifty day moving average price is $255.06 and its 200-day moving average price is $247.32. The stock has a market cap of $179.40 billion, a PE ratio of 41.05, a price-to-earnings-growth ratio of 3.68 and a beta of 0.83. The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. Danaher Co. has a one year low of $182.09 and a one year high of $269.11.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. Danaher’s quarterly revenue was down 2.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.36 EPS. On average, equities research analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. The ex-dividend date is Friday, June 28th. Danaher’s payout ratio is 18.31%.

Wall Street Analysts Forecast Growth

Several research firms recently commented on DHR. Robert W. Baird boosted their target price on Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 24th. Bank of America boosted their target price on Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 24th. Evercore ISI reduced their target price on Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. TD Cowen boosted their target price on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Finally, HSBC upgraded Danaher from a “hold” rating to a “buy” rating and boosted their target price for the stock from $250.00 to $280.00 in a research report on Wednesday, April 17th. Six investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and a consensus price target of $268.67.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.